Workflow
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
ZACKSยท2025-10-13 19:50

Key Takeaways Protagonist Therapeutics jumped after reports of acquisition talks with JNJ surfaced.PTGX's lead drug, icotrokinra, co-developed with JNJ, is under FDA review for plaque psoriasis.The rumored deal could help JNJ offset Stelara's declining sales and expand its immunology reach.Shares of Protagonist Therapeutics (PTGX) rose 30% on Friday following a report issued by the Wall Street Journal ("WSJ"), as cited in a Yahoo Finance article, which stated that pharma giant J&J (JNJ) is interested in acq ...